Table 2.

Risk of all-cause mortality by HDL cholesterol levels in overall cohort and by eGFR category

eGFR, ml/min per 1.73 m2Hazard Ratio (95% Confidence Interval)
HDL-C≤25 mg/dlHDL-C>25 to <34 mg/dlHDL-C≥34 to ≤42 mg/dlHDL-C>42 to <50 mg/dlHDL-C≥50 mg/dl
Overall1.000.87 (0.86 to 0.88)0.84 (0.83 to 0.85)0.84 (0.82 to 0.85)0.92 (0.91 to 0.93)
≥15 to <301.000.91 (0.86 to 0.96)0.89 (0.84 to 0.94)0.92 (0.86 to 0.97)0.97 (0.91 to 1.03)
≥30 to <451.000.88 (0.85 to 0.91)0.86 (0.83 to 0.89)0.84 (0.81 to 0.87)0.88 (0.85 to 0.92)
≥45 to <601.000.85 (0.83 to 0.88)0.83 (0.80 to 0.85)0.81 (0.79 to 0.84)0.87 (0.85 to 0.89)
≥60 to <901.000.87 (0.85 to 0.89)0.83 (0.82 to 0.85)0.84 (0.82 to 0.86)0.91 (0.89 to 0.93)
≥901.000.85 (0.83 to 0.88)0.84 (0.82 to 0.87)0.85 (0.82 to 0.88)1.01 (0.97 to 1.04)
  • Models were adjusted for age, race, cancer, cerebrovascular accident, chronic lung disease, diabetes mellitus, dementia, hepatitis C, HIV, hypertension, body mass index, LDL cholesterol, triglycerides, serum albumin, angiotensin–converting enzyme inhibitor/angiotensin receptor blocker use, coronary artery disease, congestive heart failure, and peripheral artery disease. Models were additionally adjusted for eGFR, dialysis, kidney transplant, and statin use as time varying. P for interaction of HDL-C and eGFR category is <0.01. HDL-C, HDL cholesterol.